AI Science Tracker

Artificial intelligence-based identification of octenidine as a Bcl-xL inhibitor.

Korea Research Institute of Bioscience and Biotechnology; Korea Advanced Institute of Science and Technology; Korea University of Science and Technology · 20 Dec 2021 · medicine

Discovery

Artificial intelligence-based identification of octenidine as a Bcl-xL inhibitor.

Source check: Source checked. Not independent scientific confirmation.

Finding: Deep-learning and docking screening nominated octenidine as a Bcl-xL binder. The abstract reports NMR binding, reduced intracellular Bcl-xL/Bak interaction and cancer-cell effects; full-text methods and quantitative assay details were not assessed.

Technology: Structural-feature-based deep learning plus molecular docking

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

AI contribution
The primary abstract reports structural-feature-based deep learning and molecular docking to screen an approved-drug library; architecture, training data and candidate denominator were not assessable from the abstract.
Test and result
The primary abstract reports NMR binding to the Bcl-xL BH3-binding region, NanoBiT inhibition of Bcl-xL/Bak-BH3 interaction in cells, and apoptosis-associated proliferation inhibition in MCF-7 and H1299 cells. Denominators and quantitative potency were not stated in the reviewed abstract.
Limitation / still unknown
Only the PubMed abstract and metadata were reviewed. Full-text methods, concentrations, denominators, quantitative binding data and detailed controls were not assessed; cell results do not establish treatment efficacy.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://doi.org/10.1016/j.bbrc.2021.12.061

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 18 Nov 2026. Review scope: Primary PubMed abstract and bibliographic metadata only; full text not reviewed..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open in the full catalog for filters, charts and related discoveries. Browse medicine discoveries.